Blavatnik Biomedical Accelerator


From innovation to impact

Biomedical research at Harvard has the potential to improve countless lives, revolutionize industries, and create immense social and economic value. Translating this early-stage research into compelling, validated technologies requires careful planning, focused resources, and a tireless pursuit of results.

The Blavatnik Biomedical Accelerator guides Harvard scientists toward translational impact by providing strategic, monetary, and advisory support for well-defined research projects. Our work is expressly aimed at hastening the pace of scientific progress, developing a shared vision with partners in industry, and ensuring that lifesaving technologies born at Harvard will become new products that impact the world for the better.

Read about the new research projects supported in 2018.

Blavatnik Biomedical Accelerator - overview brochure

Learn more about our tried-and-true approach in the Blavatnik Biomedical Accelerator brochure (PDF).

Proving the value of big ideas

The Accelerator seeks to support innovative, investigator-initiated research, and to develop preliminary observations into robust intellectual property positions. Its primary goal is to advance technologies to the point where an industry partnership can commence.

We employ a proven strategy of selecting projects with significant commercial potential, and providing financial support and domain expertise to fuel translational research, proof-of-concept, and technological development. We simultaneously build relationships with industry, generating partnerships and licensing opportunities, and facilitating startup formation and investment.

Expanding Our Impact

The Accelerator dramatically expanded its capabilities in 2013 thanks to a major gift from the Blavatnik Family Foundation.

Learn More

Recent Blavatnik News

View All Blavatnik News


By helping translate the inventions that happen here at Harvard into projects and businesses with real-world impact, the Accelerator can provide a unique and powerful spur to collaboration and innovation – both of which are crucial to solving society's most difficult challenges.

Nitin Nohria

Dean, Harvard Business School

The Blavatnik Biomedical Accelerator Advisory Committee

The Blavatnik Biomedical Accelerator Advisory Committee comprises academic thought leaders and accomplished members of the biopharma and life-science venture communities. This distinguished group provides critical input on project selection and oversight, helping to ensure that research work plans have been designed to drive results, add value, and effectively address key criteria for licensing.

Atlas Venture

Third Rock Ventures

Hsien Wu and Daisy Yen Wu Professor of Biological Chemistry and Molecular Pharmacology
Harvard Medical School

Formerly CSO
Nimbus Therapeutics

Morton Grove-Rasmussen Professor of Immunohematology
Harvard Medical School

Managing Director
Healthcare Ventures

Chairman, Vir Biotechnology
Chairman, Denali Therapeutics

Founder, President, and CEO
FORMA Therapeutics

F-Prime Biomedical Research Initiative

New projects in 2018

In labs across Harvard University, 11 innovative research projects received new support from the Blavatnik Biomedical Accelerator in 2018. Our investigators are advancing crucial translational work in the areas of drug delivery, cancer, regenerative medicine, neuroscience, infectious disease, and therapeutics development for kidney disease, deafness, and heart failure. These projects are driving rapidly toward commercial partnership. To learn more, please contact us.

Drug Delivery

Delivery of Therapeutic Monoclonal Antibodies via Acoustophoretic Printing
Jennifer Lewis
Hansjorg Wyss Professor of Biologically Inspired Engineering and Jianming Yu Professor of Arts and Sciences, Harvard John A. Paulson School of Engineering and Applied Sciences

Oral Delivery of Biologics using Ionic Liquids
Samir Mitragotri
Hiller Professor of Bioengineering and Hansjorg Wyss Professor of Biologically Inspired Engineering, Harvard John A. Paulson School of Engineering and Applied Sciences


Development of an Antibody to Alter a Novel Immune Checkpoint Inhibitor
David Scadden
Gerald and Darlene Jordan Professor of Medicine and Professor of Stem Cell and Regenerative Biology, Harvard Medical School and Harvard Faculty of Arts and Sciences

Targeting a Key Pathogenic Factor of Cachexia Caused by Cancer
Norbert Perrimon
James Stillman Professor of Developmental Biology, Harvard Medical School

Regenerative Medicine

Developing Novel Geroprotein Agents to Combat Age-related Muscle Pathologies
Amy Wagers
Forst Family Professor of Stem Cell and Regenerative Biology, Harvard College Professor, Harvard Medical School and Harvard Faculty of Arts and Sciences

New Methods to Differentiate Human Stem Cells
George Church
Robert Winthrop Professor of Genetics, Harvard Medical School


Compounds for the Treatment of Tactile Hypersensitivity in Autism Spectrum Disorders
David Ginty
Edward R. and Anne G. Lefler Professor of Neurobiology, Harvard Medical School

Infectious Disease

Development of Small Molecules with Broad-spectrum Activity Against the Flaviviruses Including Dengue and Zika
Priscilla Yang
Associate Professor of Microbiology and Immunobiology, Harvard Medical School

Therapeutics Development for Kidney Disease, Deafness, and Heart Failure

Polycystic Kidney Disease: Mechanistic Dissection and Discovering Therapeutic Targets
Adrian Salic
Professor of Cell Biology, Harvard Medical School

Discovery of Gene Regulatory Elements for Treating Hereditary Deafness
David Corey
Bertarelli Professor of Translational Medical Science, Harvard Medical School

Relaxin Receptor Agonists as Next-generation Therapies for Heart Failure
Andrew Kruse
Associate Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School